Introducing Migraine

Migraine is a severe neurological disorder characterized by recurrent headaches that are typically throbbing, often unilateral, and accompanied by symptoms such as nausea, vomiting, and extreme sensitivity to light (photophobia) and sound (phonophobia). 

These attacks can be debilitating, significantly impacting a person's daily life and productivity.

While various medications are used for acute treatment and prevention, many patients still experience insufficient relief or struggle with undesirable side effects.

Deep Transcranial Magnetic Stimulation (Deep TMS) represents an innovative, non-invasive approach being explored for migraine management.

This therapy uses magnetic pulses to stimulate specific brain regions involved in pain processing and migraine pathways. 

Deep TMS offers advantages such as being an outpatient procedure, generally well-tolerated, and having minimal systemic side effects compared to oral medications.

Research indicates its potential in helping to reduce migraine frequency and severity for some patient.

A Different Approach to Treatment

Deep TMS offers a fundamentally different approach. As a non-invasive, outpatient procedure, it bypasses the need for hospitalization or anesthesia, providing a more convenient and less disruptive treatment experience. 

Crucially, by delivering highly targeted magnetic stimulation directly to specific brain regions, Deep TMS works at the neurological source of various conditions, rather than affecting the entire body. 

This targeted action translates into minimal systemic side effects, often limited to mild, transient discomfort at the treatment site. 

For many patients who find conventional therapies insufficient or intolerable, Deep TMS offers a well-tolerated and effective alternative or adjunctive option, providing renewed hope for meaningful symptom improvement and better long-term outcomes.

You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.

However, BrainsWay Deep TMS™ has received the European CE Mark for the treatment of many conditions.

This significant approval underscores the therapy's established safety and efficacy for these indications in Europe. While regulatory statuses vary by region, this CE Mark highlights the recognized potential of Deep TMS as a therapeutic option for:

Major Depressive Disorder (MDD)

Anxiety Depression

Obsessive-Compulsive Disorder (OCD)

Smoking Cessation

Alzheimer's Disease (AD)

Autism

Bipolar Disorder

Chronic Pain

Multiple Sclerosis (MS)

Parkinson's Disease

Post-Stroke Rehabilitation

Post-Traumatic Stress Disorder (PTSD)

Negative Symptoms of Schizophrenia